Highlights

• Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) declined 5.01% to ₹1,631.10 on April 10, 2026.
• The stock has fallen below its 50-day SMA of ₹1,729.94, indicating that near-term momentum has weakened.
• RSI slipped to 31.39, showing that the stock is approaching oversold territory.

Overview

Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) came under pressure on April 10, 2026, with the stock falling 5.01% to ₹1,631.10. The stock opened at ₹1,699.20 and touched an intraday high of ₹1,700.00 before extending losses through the session.

The decline comes after the stock struggled to sustain above the ₹1,750.00 region over the past few weeks. The latest move has pushed the stock to its lowest level in more than two months.

Fundamental View

For the quarter ended December 2025, Sun Pharmaceutical Industries Limited reported consolidated total income of ₹16,09,938.00 lakh. Profit before tax stood at ₹4,22,716.00 lakh, while net profit came in at ₹3,38,117.00 lakh. Earnings per share for the quarter was ₹14.00.

The company continues to report strong profitability and healthy earnings. However, the recent fall in the stock suggests that market sentiment has weakened despite the strong financial performance.

Technical View

Sun Pharmaceutical Industries Limited is currently trading near ₹1,631.10 and has slipped below its 50-day Simple Moving Average of ₹1,729.94. The stock had been holding above this moving average for most of late 2025 and early 2026, but the latest decline indicates that the broader structure has weakened.

The chart shows that Sun Pharma attempted to stabilise after touching the ₹1,800.00 region in March 2026. However, repeated selling near higher levels has resulted in a sharp reversal. The latest candle reflects strong downside pressure and suggests that sellers remain active.

The 14-day RSI is currently at 31.39, which is close to the oversold zone and indicates weak momentum. Unless the stock quickly moves back above the recent trading range, the near-term trend may continue to remain under pressure.

Key Technical Levels

On the downside, the immediate support zone is placed between ₹1,570.00 and ₹1,450.00. A move below ₹1,570.00 could increase downside pressure further.

On the upside, Sun Pharmaceutical Industries is likely to face resistance between ₹1,750.00 and ₹1,800.00. The stock may need to reclaim this zone to improve the near-term structure.

Source: TradingView

Risks To Watch

• The stock has slipped below its 50-day SMA.
• RSI near 31.39 reflects weakening momentum.
• Failure to hold above ₹1,570.00 may lead to further downside.
• Repeated rejection near ₹1,750.00 may keep the trend under pressure.

Summary

Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) remains under pressure after falling more than 5.00% and breaking below its 50-day SMA. While the company’s financial performance remains strong, the chart structure has weakened significantly in the near term. Traders may now watch whether the stock can hold above the ₹1,570.00 zone or continue to move lower.